Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial.

Pappas, Peter G; Vazquez, Jose A; Oren, Ilana; Rahav, Galia; Aoun, Mickael; Bulpa, Pierre; Ben-Ami, Ronen; Ferrer, Ricard; Mccarty, Todd; Thompson, George R; Schlamm, Haran; Bien, Paul A; Barbat, Sara H; Wedel, Pamela; Oborska, Iwona; Tawadrous, Margaret; Hodges, Michael R

Pappas, Peter G; Vazquez, Jose A; Oren, Ilana; Rahav, Galia; Aoun, Mickael; Bulpa, Pierre; Ben-Ami, Ronen; Ferrer, Ricard; Mccarty, Todd; Thompson, George R; Schlamm, Haran; Bien, Paul A; Barbat, Sara H; Wedel, Pamela; Oborska, Iwona; Tawadrous, Margaret; Hodges, Michael R.

Affiliation

Pappas PG; Division of Infectious Diseases, Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Vazquez JA; Division of Infectious Disease, Department of Medicine, Medical College of Georgia/Augusta University, Augusta, GA, USA.
Oren I; Infectious Disease Unit, Rambam Health Care Campus, Haifa, Israel.
Rahav G; Sheba Medical Center, Ramat Gan, Israel.
Aoun M; Chaim Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Bulpa P; Department of Internal Medicine, Institut Jules Bordet, Brussels, Belgium.
Ben-Ami R; Intensive Care Medicine, University Hospital Mont-Godinne, CHU UCL Namur, Yvoir, Belgium.
Ferrer R; Chaim Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Mccarty T; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Thompson GR; Vall d'Hebron Hospital Universitari, Shock, Organ Dysfunction, and Resuscitation (SODIR) Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d´Hebron Barcelona Hospital Campus, Passeig de la Vall d'Hebron, Barcelona, Spain.
Schlamm H; Division of Infectious Diseases, Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Bien PA; Division of Infectious Diseases, Department of Internal Medicine, and Department of Medical Microbiology and Immunology, University of California Davis, Sacramento, CA, USA.
Barbat SH; Amplyx Pharmaceuticals Inc., San Diego, CA, USA.
Wedel P; Pfizer, Inc., Groton, CT, USA.
Oborska I; Amplyx Pharmaceuticals Inc., San Diego, CA, USA.
Tawadrous M; Amplyx Pharmaceuticals Inc., San Diego, CA, USA.
Hodges MR; Amplyx Pharmaceuticals Inc., San Diego, CA, USA.

J Antimicrob Chemother ; 78(10): 2471-2480, 2023 10 03.

Article de En | MEDLINE | ID: mdl-37596890

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Candidémie / Antifongiques Type d'étude: Clinical_trials Limites: Adult / Humans Langue: En Journal: J Antimicrob Chemother Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google